Preclinical Development Of A Therapeutic Anticancer Antibody To C-Met
Funder
National Health and Medical Research Council
Funding Amount
$435,530.00
Summary
Many common cancers cannot be effectively treated. A range of these cancers (e.g. gastric and lung cancer) display the molecule c-Met on their cell surface. c-Met promotes tumour growth; therefore, blocking c-Met is a promising strategy for treating these cancers. However, no antibodies or drugs that target c-Met have been licensed. The therapeutics that are being developed to target c-Met all have considerable limitations. Thus, there is an opportunity to develop a 'best-in-class' therapeutic.
The Psychology of Misinformation—Towards A Theory-driven Understanding. The project aims to develop a psychological theory of misinformation effects. Misinformation influences people’s memory, reasoning and decision-making even after corrections – it thus poses a significant challenge for science and society. Through the combination of systematic experimentation with theory-driven computational modelling, the project will strive to concurrently consider individual-level cognition and the impact ....The Psychology of Misinformation—Towards A Theory-driven Understanding. The project aims to develop a psychological theory of misinformation effects. Misinformation influences people’s memory, reasoning and decision-making even after corrections – it thus poses a significant challenge for science and society. Through the combination of systematic experimentation with theory-driven computational modelling, the project will strive to concurrently consider individual-level cognition and the impact of sociocultural context. It is anticipated that this novel integrative approach will substantially expand our understanding of misinformation effects, and that this theoretical progress will result in the formulation of specific communication strategies to reduce the impact of misinformation on society.Read moreRead less
Improving Interpreting For Dementia Assessments: The MINDSET Study
Funder
National Health and Medical Research Council
Funding Amount
$271,586.00
Summary
The MINDSET Study aims to improve the quality of communication in an interpreter mediated cognitive assessment for dementia. Working with interpreters, clinicians, culturally and linguistically diverse people with dementia, and their carers we will co-design, trial, and implement national online training targeted at interpreters. This training will enable interpreters to be prepared and confident in performing their role impartially, effectively, and accurately.
Aspirin For The Prevention Of Cognitive Decline In The Elderly: A Neuro-Vascular Imaging Study (ENVIS-ion) From ASPREE
Funder
National Health and Medical Research Council
Funding Amount
$1,341,232.00
Summary
The ENVIS-ion trial will examine whether Aspirin is effective in delaying the onset of worsening of thinking and memory abilities in healthy older adults. Magnetic resonance imaging (MRI) of brain structure will detect markers of early worsening of thinking and memory abilities. Blood vessels in the back of the eye (retina) share many features with vessels in the brain. We will compare whether aspirin lessens changes over time of features shown with brain MRI and retinal photography.
From fluid intelligence to crystallised expertise: an integrative Bayesian approach. Intelligence is correlated with learning but uncorrelated with most aspects of expertise. Why is this so? Why does the role of intelligence diminish as one becomes more expert at a task? This project examines a broad range of cognitive tasks to provide a concise mathematical description of how intelligence relates to expertise.
AusDiab 3: Emerging Risk Factors For And Long-term Incidence Of Cardio-metabolic Diseases
Funder
National Health and Medical Research Council
Funding Amount
$2,616,397.00
Summary
This study will track 11,000 Australian adults over 12 years to determine how many develop diabetes, obesity, kidney and heart disease. The study will develop ways to best predict those who are going to develop these conditions before they have arisen, and will explore a range of novel risk factors to better understand these conditions.
Most eye diseases have a genetic contribution, whether rare disorders affecting children such as retinoblastoma or congenital cataracts through to common disorders of older people such as myopia, age-related macular degeneration or glaucoma. We will continue our successful research to find genes that cause these diseases and use this to improve patient care and prevent blindness. We will work out how families can use this genetic information to participate in trials to develop new treatments.
Antimalarial Drugs In Pregnancy: Preclinical And Clinical Studies Of Conventional And Novel Agents
Funder
National Health and Medical Research Council
Funding Amount
$470,115.00
Summary
Women in malaria-endemic areas such as coastal PNG are at high risk of malaria in pregnancy. To prevent the substantially increased malaria-associated morbidity and mortality in mother and child, and because even asymptomatic infections can be deleterious, there has been a move to giving antimalarial drugs regularly during pregnancy regardless of the mother's clinical or parasitological status. In poor tropical countries, such treatment usually comprises safe and inexpensive agents such as chlor ....Women in malaria-endemic areas such as coastal PNG are at high risk of malaria in pregnancy. To prevent the substantially increased malaria-associated morbidity and mortality in mother and child, and because even asymptomatic infections can be deleterious, there has been a move to giving antimalarial drugs regularly during pregnancy regardless of the mother's clinical or parasitological status. In poor tropical countries, such treatment usually comprises safe and inexpensive agents such as chloroquine and Fansidar. There are two main issues with this approach. First, the efficacy of such conventional agents is waning and this increases the risk of break-through malaria. Second, there are few data on how the drugs are handled in pregnancy on which to base recommendations for treatment. We plan to collect information on the disposition and effectiveness of chloroquine and Fansidar in women with malaria in pregnancy in PNG that should allow a critical appraisal of the usefulness of current regimens in PNG and in other tropical countries where parasite resistance to these agents is emerging. Artemisinin combination therapy (ACT) in the form of a novel artemisinin drug and a longer-acting partner has been suggested as the most promising alternative therapy for malaria in pregnancy if conventional drugs fail. We plan to assess the safety of a leading ACT formulation, namely dihydroartemisinin and the chloroquine-like drug piperaquine (DHA-PQ), in animals before extending our studies to women with malaria in PNG. These latter studies will allow an evaluation of the safety and efficacy of DHA-PQ as novel therapy for malaria in pregnancy in PNG and other tropical countries.Read moreRead less
ARC/NHMRC Research Network in Ageing Well. The ARC Research Network on Ageing Well will support interdisciplinary, high quality research in the National Research Priority Goal of Ageing Well, Ageing Productively. It will build scale and focus on Australia's notable research strengths in ageing, promote collaborative research, and extend research capacities. The Network will link outstanding researchers from many disciplines, nurture developing researchers, relate social to health researchers, s ....ARC/NHMRC Research Network in Ageing Well. The ARC Research Network on Ageing Well will support interdisciplinary, high quality research in the National Research Priority Goal of Ageing Well, Ageing Productively. It will build scale and focus on Australia's notable research strengths in ageing, promote collaborative research, and extend research capacities. The Network will link outstanding researchers from many disciplines, nurture developing researchers, relate social to health researchers, strengthen international collaboration, and involve and inform end-point users. It will foster research which responds to the aspirations and needs of older Australians and informs action that can improve experiences of individual and population ageing.Read moreRead less
Developing New Therapeutic Strategies For Brain Cancer
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
Each year, over 1,500 Australians will develop brain cancer. Unlike many cancers, it cannot be prevented by lifestyle changes. Adults with brain cancer usually die within 2 years. The overall aims of this funding are to extend patients' lives and build brain cancer research in Australia so that we have the best chance of curing this disease. The expected outcome is clinical trial of drug candidates for the most common and most deadly brain cancer, high-grade glioma.